万孚生物
(300482)
| 流通市值：94.93亿 | | | 总市值：106.20亿 |
| 流通股本：4.30亿 | | | 总股本：4.81亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,245,654,367.05 | 800,275,782.51 | 3,064,809,396.66 | 2,181,361,474.64 |
| 营业收入 | 1,245,654,367.05 | 800,275,782.51 | 3,064,809,396.66 | 2,181,361,474.64 |
| 二、营业总成本 | 1,069,201,644.31 | 588,132,685.22 | 2,433,963,779.68 | 1,715,728,355.95 |
| 营业成本 | 462,548,481.08 | 266,703,767.01 | 1,098,880,165.75 | 797,669,919.04 |
| 税金及附加 | 5,403,581.09 | 3,616,536.27 | 15,493,769.11 | 7,250,386.23 |
| 销售费用 | 318,913,059.05 | 158,971,793.4 | 683,498,956.43 | 472,005,966.72 |
| 管理费用 | 91,430,935.82 | 52,419,623.44 | 222,355,215.48 | 153,220,061.93 |
| 研发费用 | 174,217,875.75 | 103,101,058.36 | 411,516,186.87 | 271,181,881.59 |
| 财务费用 | 16,687,711.52 | 3,319,906.74 | 2,219,486.04 | 14,400,140.44 |
| 其中:利息费用 | 15,249,638.48 | 7,532,510.22 | 30,472,622.07 | 21,634,826.15 |
| 其中:利息收入 | 2,475,528.68 | 1,884,531.79 | 18,607,357.64 | 16,320,029.41 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 17,604,203.48 | 11,431,121.13 | 29,617,794.26 | 24,424,625.34 |
| 加:投资收益 | 9,519,032.06 | -406,776.11 | 1,920,270.34 | 1,964,002.7 |
| 资产处置收益 | -2,089.9 | - | 759,635.83 | 736,983.24 |
| 资产减值损失(新) | 4,207,021.92 | -102,886.4 | -12,403,263.34 | - |
| 信用减值损失(新) | -10,386,319.79 | -12,118,014.68 | -38,763,502.17 | -18,095,942.9 |
| 其他收益 | 10,447,058.09 | 4,659,609.86 | 24,868,736.28 | 23,445,130.67 |
| 四、营业利润 | 207,841,628.6 | 215,606,151.09 | 636,845,288.18 | 498,107,917.74 |
| 加:营业外收入 | 827,571.2 | 516,021.33 | 1,463,959.23 | 1,072,523.02 |
| 减:营业外支出 | 3,892,218.41 | 1,104,366.31 | 8,846,637.25 | 6,344,520.16 |
| 五、利润总额 | 204,776,981.39 | 215,017,806.11 | 629,462,610.16 | 492,835,920.6 |
| 减:所得税费用 | 14,567,109.49 | 24,945,584.07 | 64,247,476.36 | 53,019,650 |
| 六、净利润 | 190,209,871.9 | 190,072,222.04 | 565,215,133.8 | 439,816,270.6 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 190,209,871.9 | 190,072,222.04 | 565,215,133.8 | 439,816,270.6 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 189,198,935.53 | 189,135,410.14 | 561,628,533.81 | 435,935,866.11 |
| 少数股东损益 | 1,010,936.37 | 936,811.9 | 3,586,599.99 | 3,880,404.49 |
| 扣除非经常损益后的净利润 | 153,547,946.09 | 171,973,050.72 | 497,445,110.89 | 387,513,192.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.39 | 0.39 | 1.21 | 0.94 |
| (二)稀释每股收益 | 0.39 | 0.39 | 1.21 | 0.94 |
| 八、其他综合收益 | -37,344.56 | -27,967.44 | -27,150,639.65 | -222,870.57 |
| 归属于母公司股东的其他综合收益 | -37,344.56 | -27,967.44 | -27,150,639.65 | -222,870.57 |
| 九、综合收益总额 | 190,172,527.34 | 190,044,254.6 | 538,064,494.15 | 439,593,400.03 |
| 归属于母公司股东的综合收益总额 | 189,161,590.97 | 189,107,442.7 | 534,477,894.16 | 435,712,995.54 |
| 归属于少数股东的综合收益总额 | 1,010,936.37 | 936,811.9 | 3,586,599.99 | 3,880,404.49 |
| 公告日期 | 2025-08-20 | 2025-04-25 | 2025-04-10 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |